Translating Feedback Into Change
IVI’s Open-Source Value Project (OSVP) models improve over time through an ongoing cycle of public feedback, expert review, revision, and re-release. Public comments on new model releases are the basis for later changes, but these comments must be synthesized into specific recommendations and priorities for model improvements. Technical Expert Panels fill this essential role.
For each disease-specific OSVP model released by IVI, a Technical Expert Panel of third-party subject matter experts is responsible for reviewing all public comments, identifying specific priorities for revisions, and developing a prioritized set of recommendations. These recommendations determine IVI’s revisions to the next model release.
Disease-Specific Value Models
IVI develops open-source value models for specific diseases as a laboratory for developing next-generation methods for value assessment. Two models are currently available to examine value of therapies for rheumatoid arthritis and EGFR+ non-small cell lung cancer. Select a model below to start exploring.
IVI-RA Technical Expert Panel Members

Louis Garrison, PhD, Chair
Health Economist
University of Washington
Louis Garrison, PhD

Stephen Mennemeyer, PhD
Health Economist
University of Alabama
Stephen Mennemeyer, PhD
Dr. Mennemeyer’s work includes cost effectiveness or cost utility analyses regarding stroke rehabilitation, antiviral therapy for neonatal herpes simplex virus, and drug abuse treatment for the homeless as well as other studies on child obesity, health care labor, clinical laboratory competitive bidding and patient response to hospital mortality information. Recently he developed a discrete event simulation model to examine the cost effectiveness of earlier cataract surgery as a strategy for reducing motor vehicle collision. He is currently working on an Agent Based simulation model to examine how treating HIV + women for depression may affect their adherence to HIV therapy and the transmission of the HIV virus.

Kaleb Michaud, PhD
Epidemiologist
University of Nebraska
Kaleb Michaud, PhD

Elizabeth Perkins, MD
Rheumatologist
Rheumatology Care Center
Elizabeth Perkins, MD

Carole Wiedmeyer, MBA
Rheumatoid Arthritis Patient Researcher
Carole Wiedmeyer, MBA
In addition to her work as a patient researcher, Ms. Wiedmeyer serves as a Patient Governor with the Global Healthy Living Foundation’s (GHLF) ArthritisPower initiative, which established a network of thousands of arthritis patients dedicated to participating in arthritis research. During that time, she spearheaded the formation of the GHLF Patient Partners in Research, which expands the pool of patient volunteers who are trained in research methods and available to collaborate directly with academic researchers on arthritis research.
IVI-NSCLC Technical Expert Panel Members

Jhanelle Gray, MD
Medical Oncologist
H. Lee Moffit Cancer Center and Research Institute
Jhanelle Gray, MD

Ticiana Leal, MD
Assistant Professor of Medicine
University of Wisconsin – Madison
Ticiana Leal, MD

Daryl Pritchard, PhD
Senior Vice President, Science Policy
Personalized Medicine Coalition
Daryl Pritchard, MD
Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council (NPC). Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Industry Organization (BIO).
Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics (ASHG)/National Human Genome Research Institute (NHGRI) Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.

Diane Spry
Patient
Diagnosed with Stage IV Lung Cancer
Diane Spry
